12-Feb-2020 - Bayer AG

Bayer and Nuvisan create new research unit in Berlin

Bayer to retain significant research activities and headquarters for the company’s Pharmaceuticals Division in Berlin

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in Germany and France. The strategic partnership will lay the foundation for a brand-new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer’s increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.

“With Nuvisan we have found an excellent partner with a clear plan to build up a strong full-fledged research unit in Berlin together with our dedicated team of scientists,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development. “Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists.”

The Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. The research center comes with capabilities and capacities spanning the entire drug discovery value chain, including Lead Discovery, Medicinal Chemistry, Pharmacology, Drug Metabolism & Pharmacokinetics, Investigational Toxicology, and Animal Management. Bayer will retain significant research activities in Berlin, which remains the headquarters for the company’s Pharmaceuticals Division and one of its major global research sites.

“With these new drug discovery capabilities and capacities, we do not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology,” says Dr. Dietrich Bruchmann, CEO and managing partner of Nuvisan. “The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials.”

Bayer and Nuvisan will cooperate closely in the coming years to build the new research center. The transaction is expected to close mid of 2020 subject to successful completion of the consultation process with the employee representatives and the preparations for taking over the research activities.

Facts, background information, dossiers
More about Bayer
  • News

    Bayer: successful start to 2021

    The Bayer Group had a successful start to 2021. “We’re seeing a good operational performance overall, but we were impacted by negative currency effects as expected,” said CEO Werner Baumann when the quarterly statement for the first quarter of 2021 was published on Wednesday. “Our Crop Scie ... more

    Bayer: Early indications of a successful start to 2021

    In 2020 the Bayer Group weathered the COVID-19 pandemic well from an operational point of view. “That shows very clearly that we are active in the right industries. After all, few things are more important to people than health and nutrition,” said Werner Baumann, Chairman of the Board of M ... more

    Bayer delivers robust performance despite pandemic

    The Bayer Group delivered robust operational performance in 2020. “Our operational strength in these turbulent times shows just how resilient our businesses are, even during the pandemic,” said Werner Baumann, Chairman of the Board of Management, on Thursday during the company’s Financial N ... more

  • Companies

    Bayer Hispania, S.L.

    more

    Química Farmacéutica Bayer, S.L.

    more

    Bayer Sp. z o.o.

    Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more

  • Associations

    Bayer USA Foundation

    Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more

More about Nuvisan Pharma Services